Pyridine and pyrazine derivative for the treatment of CF

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO RE46757
SERIAL NO

14755691

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • NOVARTIS AG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baettig, Urs Horsham, GB 24 177
Bala, Kamlesh Jagdis Horsham, GB 21 156
Budd, Emma Horsham, GB 21 207
Edwards, Lee Horsham, GB 33 340
Howsham, Catherine Horsham, GB 29 238
Hughes, Glyn Alan Horsham, GB 7 23
Legrand, Darren Mark East Grinstead, GB 23 207
Spiegel, Katrin Horsham, GB 10 139

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 20, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 20, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00